Search

Ajamete Noele Kaykas

from San Francisco, CA
Age ~53
Get Report
Also known as:
Ajamete N Kaykas, Ajamete A Kaykas, Ajamete K Kaykas, Noele Kaykas, Ajanet Kayka, Noele Briggs Aprile, Kaykas Ajamete, E S
Related to:
Dale L JohnsonRoss Johnson, 59Deborah Fleming, 40Elena Ferrara, 89Kenneth Zaretzke, 92Christopher Johnson, 41
Connected to:
Rebecca Kaykas-Wolff, 54Marina I Kaykova, 43Ann M Kayl, 68Germaine F Kayl, 85Hiroko K Kayl, 57Jesse Kayl, 43Linda R Kayl, 102Paul M Kayl, 39Rebecca J Kayl, 67Andrew R Kayla, 66

Ajamete Kaykas Phones & Addresses

  • San Francisco, CA
  • Cambridge, MA
  • 6516 17Th St, Seattle, WA 98115 (206) 784-0390
  • 137 80Th St, Seattle, WA 98117 (206) 784-0390
  • 1619 67Th St, Seattle, WA 98117
  • 2602 Fairfield Pl, Madison, WI 53704 (608) 244-6558

Work

Company: Insitro Nov 2018 Position: Vice president high-throughput biology

Education

Degree: Doctorates, Doctor of Philosophy School / High School: University of Wisconsin - Madison 1996 to 2001 Specialities: Molecular Biology, Virology

Skills

Molecular Biology • Cell • Cell Culture • Cell Biology • Biotechnology • Proteomics • Drug Discovery • Functional Genomics • Assay Development • Protein Chemistry • Protein Purification • Bioinformatics • Lifesciences • Microscopy • Computational Biology

Industries

Biotechnology

Resumes

Resumes

Ajamete Kaykas Photo 1

Vice President High-Throughput Biology

View page
Location:
San Francisco, CA
Industry:
Biotechnology
Work:
Insitro
Vice President High-Throughput Biology
Novartis Institutes For Biomedical Research (Nibr) Nov 2013 - Nov 2018
Senior Investigator and Head of Neuroscience Early Target Discovery
Allen Institute For Brain Science Jun 2010 - Sep 2013
Associate Director of Functional Genomics
Vlst Corp Oct 2004 - May 2010
Associate Director of Proteomics and Informatics
University of Washington Apr 2001 - Oct 2004
Post Doc
Education:
University of Wisconsin - Madison 1996 - 2001
Doctorates, Doctor of Philosophy, Molecular Biology, Virology University of Washington 1990 - 1995
Bachelors, Bachelor of Science, Biochemistry
Skills:
Molecular Biology
Cell
Cell Culture
Cell Biology
Biotechnology
Proteomics
Drug Discovery
Functional Genomics
Assay Development
Protein Chemistry
Protein Purification
Bioinformatics
Lifesciences
Microscopy
Computational Biology

Publications

Us Patents

Methods For Identifying Polypeptide Targets And Uses Thereof For Treating Immunological Diseases

View page
US Patent:
8293500, Oct 23, 2012
Filed:
Mar 22, 2007
Appl. No.:
11/728329
Inventors:
Steven Wiley - Seattle WA, US
Craig A Smith - Seattle WA, US
Ajamete Kaykas - Seattle WA, US
Assignee:
Viral Logic Systems Technology Corp. - Seattle WA
International Classification:
C12P 21/04
US Classification:
435 701, 4241921, 530413
Abstract:
The present invention provides methods for identifying viral virulence factors and for identifying cellular polypeptides to which the viral polypeptides bind. The cellular polypeptide is useful as a therapeutic target or as a therapeutic agent for treating diseases and disorders, including immunological diseases or disorders.

Cd47 Related Compositions And Methods For Treating Immunological Diseases And Disorders

View page
US Patent:
8377448, Feb 19, 2013
Filed:
Jan 14, 2010
Appl. No.:
12/687334
Inventors:
Craig A. Smith - Seattle WA, US
Steven Wiley - Seattle WA, US
Ajamete Kaykas - Seattle WA, US
Peter Probst - Seattle WA, US
Assignee:
The Board of Trustees of the Leland Standford Junior University - Palo Alto CA
International Classification:
A61K 39/00
US Classification:
4241851, 4241921, 530300, 530810
Abstract:
Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.

Methods And Vectors For Expressing Sirna

View page
US Patent:
20050233994, Oct 20, 2005
Filed:
Apr 16, 2004
Appl. No.:
10/826130
Inventors:
Ajamete Kaykas - Seattle WA, US
Randall Moon - Kenmore WA, US
International Classification:
A61K048/00
C12Q001/68
C12N015/09
US Classification:
514044000, 435006000, 435320100
Abstract:
In a first aspect, the invention provides expression vectors comprising: (a) a first RNA polymerase III promoter operably associated with a first RNA polymerase III termination signal and (b) a second RNA polymerase III promoter operably associated with a second RNA polymerase III termination signal, wherein the first and second RNA polymerase III promoters are oriented to promote bidirectional transcription of an insert disposed between the first and the second RNA polymerase III termination signals. In other aspects, the invention provide methods for using these expression vectors for inhibiting expression of target genes, for determining the effect of siRNAs on biological processes, and for identifying siRNAs that affect biological processes.

Immunomodulatory Compositions And Uses Therefor

View page
US Patent:
20070134234, Jun 14, 2007
Filed:
Sep 29, 2006
Appl. No.:
11/541449
Inventors:
Craig Smith - Seattle WA, US
Steven Wiley - Seattle WA, US
Ajamete Kaykas - Seattle WA, US
Jalal Vakili - Seattle WA, US
Peter Probst - Seattle WA, US
Assignee:
Viral Logic Systems Technology Corp. - Seattle WA
International Classification:
A61K 39/395
C07H 21/04
C12P 21/06
C07K 16/46
C12N 5/06
C12P 21/08
US Classification:
424133100, 424178100, 530391100, 435069100, 435327000, 435320100, 536023530
Abstract:
The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-δ, and RPTP-σ, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on the host cells results in suppression of the immune response. The present invention provides agents such as antibodies, and antigen-binding fragments thereof, small molecules, aptamers, small interfering RNAs, and peptide-IgFc fusion polypeptides that interact with one or more of LAR, RPTP-δ, and RPTP-σ expressed by immune cells or interact with a polynucleotide encoding the RPTP. Also provided are RPTP Ig domain oligomers and Fc fusion polypeptides. Such agents are useful for treating an immunological disorder in a subject according to the methods described herein.

Cd47 Related Compositions And Methods For Treating Immunological Diseases And Disorders

View page
US Patent:
20080131431, Jun 5, 2008
Filed:
May 15, 2007
Appl. No.:
11/804992
Inventors:
Craig A. Smith - Seattle WA, US
Steven Wiley - Seattle WA, US
Ajamete Kaykas - Seattle WA, US
Peter Probst - Seattle WA, US
Assignee:
Viral Logic Systems Technology Corp. - Seattle WA
International Classification:
A61K 39/00
C07K 16/00
C07H 21/04
C12N 5/06
G01N 33/53
C12N 5/10
C12N 15/00
C12N 5/00
US Classification:
4241341, 5303873, 536 234, 4353201, 435325, 435375, 5303871, 435346, 4241301, 435 721
Abstract:
Provide herein are fusion polypeptides that comprise a CD47 extracellular domain or a variant thereof that is fused to a Fc polypeptide. The fusion polypeptides are useful for treating an immunological disease or disorder in a subject according to the methods described herein. The fusion polypeptides are capable of suppressing immunoresponsiveness of an immune cell, inhibiting production of proinflammatory cytokines, including inhibiting immune complex-induced production of cytokines.

Immunomodulatory Compositions And Uses Therefor

View page
US Patent:
20090117112, May 7, 2009
Filed:
Oct 6, 2008
Appl. No.:
12/246291
Inventors:
Craig A. Smith - Seattle WA, US
Steven Wiley - Seattle WA, US
Ajamete Kaykas - Seattle WA, US
Jalal Vakili - Seattle WA, US
Peter Probst - Seattle WA, US
Assignee:
VIRAL LOGIC SYSTEMS TECHNOLOGY CORPORATION - SEATTLE WA
International Classification:
A61K 39/395
C07K 16/00
A61P 37/02
US Classification:
4241361, 5303891, 53038822, 5303873, 5303911, 4241301
Abstract:
The poxvirus proteins designated A41L and 130L bind to three receptor-like protein tyrosine phosphatases (RPTP), leukocyte common antigen related protein (LAR), RPTP-δ, and RPTP-σ, that are present on the cell surface of immune cells. When a host is infected with the poxvirus, binding of A41L to cell surface proteins on the host cells results in suppression of the immune response. The present invention provides agents such as antibodies, and antigen-binding fragments thereof, small molecules, aptamers, small interfering RNAs, and peptide-IgFc fusion polypeptides that interact with one or more of LAR, RPTP-δ, and RPTP-σ expressed by immune cells or interact with a polynucleotide encoding the RPTP. Also provided are RPTP Ig domain oligomers and Fc fusion polypeptides. Such agents are useful for treating an immunological disorder in a subject according to the methods described herein.

Methods For Identifying Polypeptide Targets And Uses Thereof For Treating Immunological Diseases

View page
US Patent:
20130129748, May 23, 2013
Filed:
Sep 14, 2012
Appl. No.:
13/616694
Inventors:
Steven Wiley - Seattle WA, US
Craig A. Smith - Seattle WA, US
Ajamete Kaykas - Seattle WA, US
Assignee:
Viral Logic Systems Technology Corp. - Seattle WA
International Classification:
G01N 33/68
A61K 39/395
C12Q 1/70
US Classification:
4241721, 435 724, 435 721, 435 723, 435 5, 435 613, 435 61
Abstract:
The present invention provides methods for identifying viral virulence factors and for identifying cellular polypeptides to which the viral polypeptides bind. The cellular polypeptide is useful as a therapeutic target or as a therapeutic agent for treating diseases and disorders, including immunological diseases or disorders.

Predicting Disease Outcomes Using Machine Learned Models

View page
US Patent:
20210366577, Nov 25, 2021
Filed:
Jun 17, 2021
Appl. No.:
17/350761
Inventors:
- South San Francisco CA, US
Ajamete Kaykas - San Francisco CA, US
Eilon Sharon - Menlo Park CA, US
Cecilia Giovanna Silvia Cotta-Ramusino - Cambridge MA, US
Mohammad Muneeb Sultan - San Francisco CA, US
Panagiotis Dimitrios Stanitsas - Palo Alto CA, US
Francesco Paolo Casale - San Francisco CA, US
Adam Joseph Riesselman - Brisbane CA, US
Lorn Kategaya - Oakland CA, US
Max R. Salick - South San Francisco CA, US
International Classification:
G16B 40/20
G16H 50/20
G06N 20/00
G16B 50/30
Abstract:
Embodiments of the disclosure include implementing a ML-enabled cellular disease model for validating an intervention, identifying patient populations that are likely responders to an intervention, and developing a therapeutic structure-activity relationship screen. To generate a cellular disease model, data is combined from human genetic cohorts, from the literature, and from general-purpose cellular or tissue-level genomic data to unravel the set of factors (e.g., genetic, environmental, cellular factors) that give rise to a particular disease. In vitro cells are engineered using the set of factors to generate training data for training machine learning models that are useful for implementing cellular disease models.
Control profile
Ajamete Noele Kaykas from San Francisco, CA, age ~53 Get Report